Evidence map›Paper›PMID 34641473›Full record

ArticleMolecules (Basel, Switzerland)2021

Computational Approaches for the Design of Novel Anticancer Compounds Based on Pyrazolo[3,4-d]pyrimidine Derivatives as TRAP1 Inhibitor.

Amena Ali, Magda H Abdellattif, Abuzer Ali, Ola AbuAli, Mohd Shahbaaz, Mohamed Jawed Ahsan, Mostafa A Hussien

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Synthesis of New Pyrazolo[3,4-Molecules (Basel, Switzerland) · 2024
    Article
  2. Thiazolo-pyridopyrimidines: AnBioImpacts : BI · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Amena AliDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0001-8463-5182
Magda H AbdellattifDepartment of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Abuzer AliDepartment of Pharmacognosy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.ORCID 0000-0002-4313-3896
Ola AbuAliDepartment of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Mohd ShahbaazSouth African Medical Research Council Bioinformatics Institute, University of Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa.
Mohamed Jawed AhsanDepartment of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Ambabari Circle, Jaipur 302039, India.ORCID 0000-0002-6919-5489
Mostafa A HussienDepartment of Chemistry, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-4803-167X
Taif University · SASouth Ural State University · RUKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present in-silico study, various computational techniques were applied to determine potent compounds against TRAP1 kinase. The pharmacophore hypothesis DHHRR_1 consists of important features required for activity. The 3D QSAR study showed a statistically significant model with R

Indexed as

Antineoplastic AgentsComputer SimulationHSP90 Heat-Shock ProteinsHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationNeoplasmsPyrimidinesQuantitative Structure-Activity RelationshipAntineoplastic AgentsHSP90 Heat-Shock ProteinsLigandsPyrimidinesTRAP1 protein, human3D-QSAR pharmacophore modelingmolecular dynamics simulationsTRAP1TRAP1 kinasevirtual screening

Identifiers

PMID34641473
PMCPMC8512242
OpenAlexW3135706395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.